

## **ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009**

### **ThromboGenics’ significant achievements over the last year are recognised in nominations**

**Leuven, Belgium – 11 September, 2009** – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the “Biotech Company of the Year” and “Licensing Deal of the Year” awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a €500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of €50 million, an additional €450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fifth year running and the awards ceremony will take place on November 18, 2009 in London.

**Patrik De Haes, CEO of ThromboGenics, commented,** “We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November.”

-Ends-



**For further information please contact:**

### **ThromboGenics**

Dr. Patrik De Haes, CEO

Tel: + 32 16 75 13 10  
[patrik.dehaes@thrombogenics.com](mailto:patrik.dehaes@thrombogenics.com)

Chris Buyse, CFO

Tel: + 32 16 75 13 10  
[chris.buyse@thrombogenics.com](mailto:chris.buyse@thrombogenics.com)

### **Citigate Dewe Rogerson**

Amber Bielecka/ David Dible/ Nina Enegren

Tel: +44 (0) 207 638 95 71  
[amber.bielecka@citigatedr.co.uk](mailto:amber.bielecka@citigatedr.co.uk)

### **About ThromboGenics**

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PIGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at [www.thrombogenics.com](http://www.thrombogenics.com).

### **About Scrip World Pharmaceutical News**

Scrip World Pharmaceutical News was established in 1972 and – since that time – has continued to serve as the leading news and information source for the world's pharmaceutical and biotech industries. Scrip's team of more than 20 writers, analysts and editors provide the latest news, features and commentary from around the globe.

### ***Important information about forward-looking statements***

*Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.*